NZ193011A
(en)
|
1979-03-19 |
1983-03-15 |
Ici Australia Ltd |
Diarylamine derivatives intermediates herbicidal compositions
|
ES2054725T3
(es)
|
1987-04-21 |
1994-08-16 |
Basf Ag |
Heteroaromatos anulares de cinco miembros de p-fenoxi-fenoximetilo.
|
JP3121061B2
(ja)
|
1991-10-04 |
2000-12-25 |
塩野義製薬株式会社 |
アルコキシイミノアセトアミド類製造用中間体の製造法およびそれに用いる中間体
|
DE4137940A1
(de)
|
1991-11-18 |
1993-05-19 |
Basf Ag |
3-isoxazolylphenylverbindungen, ihre herstellung und ihre verwendung
|
US5258551A
(en)
|
1991-12-18 |
1993-11-02 |
Shionogi & Co., Ltd. |
Process for producing α-ketoamide derivative
|
AU5891494A
(en)
|
1993-01-29 |
1994-08-15 |
Nippon Soda Co., Ltd. |
Heterocyclic derivative
|
WO1994024095A1
(en)
|
1993-04-16 |
1994-10-27 |
Abbott Laboratories |
Immunosuppressive agents
|
IL112721A0
(en)
|
1994-03-10 |
1995-05-26 |
Zeneca Ltd |
Azole derivatives
|
EP0804434A1
(en)
|
1994-08-02 |
1997-11-05 |
MERCK SHARP & DOHME LTD. |
Azetidine, pyrrolidine and piperidine derivatives
|
GB9501865D0
(en)
|
1995-01-31 |
1995-03-22 |
Merck Sharp & Dohme |
Therapeutic agents
|
US5633272A
(en)
|
1995-02-13 |
1997-05-27 |
Talley; John J. |
Substituted isoxazoles for the treatment of inflammation
|
DE19536811A1
(de)
|
1995-10-02 |
1997-04-03 |
Basf Ag |
Zwischenprodukte und Verfahren zur Herstellung von substituierten Salicylsäurederivaten als Pflanzenschutzmittel
|
WO1997029774A1
(en)
|
1996-02-13 |
1997-08-21 |
G.D. Searle & Co. |
Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor
|
DE69940958D1
(de)
|
1998-12-23 |
2009-07-16 |
Glaxo Group Ltd |
Bestimmungsmethode fur liganden der nuklearen rezeptoren
|
WO2000077011A1
(en)
|
1999-06-11 |
2000-12-21 |
Allergan Sales, Inc. |
Organosilyl compounds having nuclear hormone receptor modulating activity
|
CA2429426A1
(en)
|
2000-11-17 |
2002-05-23 |
Takeda Chemical Industries, Ltd. |
Isoxazole derivatives
|
US20040131670A1
(en)
|
2001-04-17 |
2004-07-08 |
Ping Gao |
Pellicle-resistant gelatin capsule
|
US20040105885A1
(en)
|
2001-04-17 |
2004-06-03 |
Ping Gao |
Gelatin capsule exhibiting reduced cross-linking
|
US20040105884A1
(en)
|
2001-04-17 |
2004-06-03 |
Ping Gao |
Pharmaceutical dosage form comprising a sulfite compound
|
US20040105883A1
(en)
|
2001-04-17 |
2004-06-03 |
Ping Gao |
Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
|
EP1405636A4
(en)
|
2001-06-26 |
2009-04-15 |
Takeda Pharmaceutical |
REGULATOR OF RECTINTOR FUNCTION RELATING TO RETINOIDS
|
US20070010562A1
(en)
|
2001-08-13 |
2007-01-11 |
Ulrike Bauer |
Nr1h4 nuclear receptor binding compounds
|
DE60131967D1
(de)
|
2001-08-13 |
2008-01-31 |
Phenex Pharmaceuticals Ag |
Nr1h4-kern-rezeptor-bindende verbindungen
|
WO2003015777A1
(en)
|
2001-08-13 |
2003-02-27 |
Lion Bioscience Ag |
Nr1h4 nuclear receptor binding compounds
|
US20050107475A1
(en)
|
2002-03-21 |
2005-05-19 |
Jones Stacey A. |
Methods of using farnesoid x receptor (frx) agonists
|
US7595311B2
(en)
|
2002-05-24 |
2009-09-29 |
Exelixis, Inc. |
Azepinoindole derivatives as pharmaceutical agents
|
RU2352568C9
(ru)
|
2002-08-09 |
2009-06-27 |
Астразенека Аб |
[1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5
|
TW200812986A
(en)
|
2002-08-09 |
2008-03-16 |
Nps Pharma Inc |
New compounds
|
MXPA05001590A
(es)
|
2002-08-09 |
2005-05-23 |
Astrazeneca Ab |
Compuestos que tienen actividad en los receptores metabotropicos de glutamato.
|
EP1407774A1
(en)
|
2002-09-10 |
2004-04-14 |
LION Bioscience AG |
2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
|
AU2003290796A1
(en)
|
2002-11-14 |
2004-06-15 |
The Scripps Research Institute |
Non-steroidal fxr agonists
|
US20050143449A1
(en)
|
2002-11-15 |
2005-06-30 |
The Salk Institute For Biological Studies |
Non-steroidal farnesoid X receptor modulators and methods for the use thereof
|
WO2004048349A1
(en)
|
2002-11-22 |
2004-06-10 |
Smithkline Beecham Corporation |
Farnesoid x receptor agonists
|
WO2004087076A2
(en)
|
2003-03-31 |
2004-10-14 |
The Rockefeller University |
Methods for inhibiting adipogenesis and for treating type 2 diabetes
|
WO2005077345A1
(en)
|
2004-02-03 |
2005-08-25 |
Astrazeneca Ab |
Compounds for the treatment of gastro-esophageal reflux disease
|
WO2005077373A2
(en)
|
2004-02-03 |
2005-08-25 |
Astrazeneca Ab |
Treatment of gastro-esophageal reflux disease (gerd)
|
US7585881B2
(en)
|
2004-02-18 |
2009-09-08 |
Astrazeneca Ab |
Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
|
AU2005245411B2
(en)
|
2004-05-14 |
2009-04-23 |
Irm Llc |
Compounds and compositions as PPAR modulators
|
MY144903A
(en)
|
2004-06-17 |
2011-11-30 |
Novartis Ag |
Pyrrolopyridine derivatives and their use as crth2 antagonists
|
WO2006044682A1
(en)
|
2004-10-13 |
2006-04-27 |
Ptc Therapeutics, Inc. |
Compounds for nonsense suppression, and methods for their use
|
JP2008137894A
(ja)
|
2005-03-22 |
2008-06-19 |
Nippon Kayaku Co Ltd |
新規なアセチレン誘導体
|
WO2006132197A1
(ja)
|
2005-06-07 |
2006-12-14 |
Shionogi & Co., Ltd. |
I型11βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物
|
RU2008128823A
(ru)
|
2005-12-15 |
2010-01-20 |
Экселиксис, Инк. (Us) |
Производные азепиноиндола в качестве фармацевтических средств
|
US7705028B2
(en)
|
2005-12-19 |
2010-04-27 |
Glaxosmithkline Llc |
Farnesoid X receptor agonists
|
US7560551B2
(en)
|
2006-01-23 |
2009-07-14 |
Amgen Inc. |
Aurora kinase modulators and method of use
|
AU2007212126B2
(en)
|
2006-02-03 |
2012-07-19 |
Eli Lilly And Company |
Compounds and methods for modulating FX-receptors
|
AU2007215207A1
(en)
|
2006-02-14 |
2007-08-23 |
Intercept Pharmaceuticals, Inc. |
Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
|
MX2008012404A
(es)
|
2006-03-28 |
2008-10-09 |
Novartis Ag |
Derivados de amida y su aplicacion para el tratamiento de enfermedades relacionadas con proteina-g.
|
WO2007118323A1
(en)
|
2006-04-17 |
2007-10-25 |
Neuromed Pharmaceuticals Ltd. |
Isoxazole derivatives as calcium channel blockers
|
PE20080259A1
(es)
|
2006-05-24 |
2008-04-10 |
Lilly Co Eli |
Compuestos y metodos para modular fxr
|
CA2651378C
(en)
|
2006-05-24 |
2012-08-28 |
Eli Lilly And Company |
Fxr agonists
|
EP2029600B1
(de)
|
2006-05-24 |
2012-03-14 |
Boehringer Ingelheim International GmbH |
Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind
|
US7932244B2
(en)
|
2006-06-27 |
2011-04-26 |
Intercept Pharmaceuticals, Inc. |
Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
|
WO2008005538A2
(en)
|
2006-07-05 |
2008-01-10 |
Exelixis, Inc. |
Methods of using igf1r and abl kinase modulators
|
NZ574621A
(en)
|
2006-07-07 |
2012-03-30 |
Boehringer Ingelheim Int |
Phenyl substituted heteroaryl-derivatives and use thereof as anti-tumour agents
|
WO2008013660A2
(en)
|
2006-07-07 |
2008-01-31 |
Biostratum, Inc. |
Inhibitors of advanced glycation end products
|
EP1894924A1
(en)
*
|
2006-08-29 |
2008-03-05 |
Phenex Pharmaceuticals AG |
Heterocyclic FXR binding compounds
|
EP1894928A1
(en)
|
2006-08-29 |
2008-03-05 |
PheneX Pharmaceuticals AG |
Heterocyclic fxr binding compounds
|
US8193225B2
(en)
|
2006-10-13 |
2012-06-05 |
The Board Of Regents Of The University Of Texas System |
Isoxazole amides, derivatives and methods of chemical induction of neurogenesis
|
CL2007003035A1
(es)
|
2006-10-24 |
2008-05-16 |
Smithkline Beechman Corp |
Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
|
US8501933B2
(en)
|
2006-11-09 |
2013-08-06 |
Roche Palo Alto Llc |
Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
|
KR20090094125A
(ko)
|
2006-12-08 |
2009-09-03 |
엑셀리시스, 인코포레이티드 |
Lxr 및 fxr 조절자
|
GB0625842D0
(en)
|
2006-12-22 |
2007-02-07 |
Argenta Discovery Ltd |
Indolizine derivatives
|
US20090105251A1
(en)
|
2007-01-25 |
2009-04-23 |
Benjamin Jones |
Renin inhibitors
|
US7511149B2
(en)
|
2007-02-09 |
2009-03-31 |
Dow Agrosciences Llc |
Process for the oxidation of certain substituted sulfilimines to insecticidal sulfoximines
|
JP5254999B2
(ja)
|
2007-02-09 |
2013-08-07 |
ダウ アグロサイエンシィズ エルエルシー |
特定の置換スルフィルイミン類を殺虫性スルホキシイミン類に酸化する方法
|
CN101641331B
(zh)
|
2007-02-26 |
2012-06-27 |
陶氏益农公司 |
制备某些取代的硫亚胺的方法
|
MX2009013624A
(es)
|
2007-06-13 |
2010-04-27 |
Glaxosmithkline Llc |
Agonistas de receptor farnesoide x.
|
JP2008308448A
(ja)
|
2007-06-15 |
2008-12-25 |
Sankyo Agro Kk |
(3−硫黄原子置換フェニル)へテロアリール誘導体
|
WO2008155054A1
(en)
|
2007-06-20 |
2008-12-24 |
F. Hoffmann-La Roche Ag |
Farnesoid-x-receptor mutants, and crystallisation thereof
|
AU2008270784A1
(en)
|
2007-07-02 |
2009-01-08 |
Glaxosmithkline Llc |
Farnesoid X receptor agonists
|
US20100240657A1
(en)
|
2007-07-02 |
2010-09-23 |
Boehringer Ingelheim International Gmbh |
Chemical compounds
|
US20090197880A1
(en)
|
2007-07-13 |
2009-08-06 |
Genelabs Technologies, Inc. |
Anti-viral compounds, compositions, and methods of use
|
KR20100056462A
(ko)
|
2007-07-13 |
2010-05-27 |
글락소스미스클라인 엘엘씨 |
항바이러스 화합물, 조성물 및 용도
|
TW200906823A
(en)
|
2007-07-16 |
2009-02-16 |
Lilly Co Eli |
Compounds and methods for modulating FXR
|
UA97847C2
(ru)
|
2007-08-01 |
2012-03-26 |
Х. Луннбек А/С |
Применение соединений, которые открывают калиевые каналы kcnq, для лечения дефицита внимания/гиперактивности (adhd) или агрессии
|
US8188080B2
(en)
|
2007-10-17 |
2012-05-29 |
Sanford-Burnham Medical Research Institute |
VHR protein tyrosine phosphatase inhibitors, compositions and methods of use
|
US20090143451A1
(en)
|
2007-11-14 |
2009-06-04 |
Andrews William H |
Compounds that increase telomerase reverse transcriptase (tert) expression and methods for using the same
|
AU2008339572B2
(en)
|
2007-12-21 |
2012-05-10 |
Astrazeneca Ab |
Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
|
EP2110374A1
(en)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
|
EP2283001A2
(en)
|
2008-05-13 |
2011-02-16 |
Boehringer Ingelheim International GmbH |
Sulfone compounds which modulate the cb2 receptor
|
US8158636B2
(en)
|
2008-05-19 |
2012-04-17 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
EP2291372A4
(en)
|
2008-05-19 |
2012-04-25 |
Burnham Inst Medical Research |
MODULATORS OF ALKALINE PHOSPHATASE FROM DARM AND APPLICATIONS THEREOF
|
EP2128158A1
(en)
|
2008-05-26 |
2009-12-02 |
Phenex Pharmaceuticals AG |
Heterocyclic cyclopropyl-substituted FXR binding compounds
|
JP5767965B2
(ja)
|
2008-06-10 |
2015-08-26 |
プレキシコン インコーポレーテッドPlexxikon Inc. |
キナーゼを調節する5h−ピロロ[2,3−b]ピラジン誘導体、およびその適応症
|
US8822513B2
(en)
|
2010-03-01 |
2014-09-02 |
Gtx, Inc. |
Compounds for treatment of cancer
|
KR20110036586A
(ko)
|
2008-06-23 |
2011-04-07 |
바스프 에스이 |
동물 해충의 퇴치를 위한 술폭시민아미드 화합물
|
WO2010006096A1
(en)
|
2008-07-11 |
2010-01-14 |
Smithkline Beecham Corporation |
Processes for the preparation of anti-viral compounds and compositions containing them
|
EP2318381A1
(en)
|
2008-08-25 |
2011-05-11 |
Dow Global Technologies LLC |
Process for preparing isoxazole compounds
|
WO2010033906A2
(en)
|
2008-09-19 |
2010-03-25 |
President And Fellows Of Harvard College |
Efficient induction of pluripotent stem cells using small molecule compounds
|
MX2011002794A
(es)
|
2008-09-25 |
2011-04-05 |
Hoffmann La Roche |
Indazol 2,3-sustituido o 4,5,6,7-tetrahidro-indazol como moduladores fxr contra dislipidemia y enfermedades relacionadas.
|
AU2009295967A1
(en)
|
2008-09-25 |
2010-04-01 |
F. Hoffmann-La Roche Ag |
3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives
|
JP2012503654A
(ja)
|
2008-09-26 |
2012-02-09 |
ワイス・エルエルシー |
1,2,3,6−テトラヒドロアゼピノ[4,5−b]インドール−5−カルボキシレート核内受容体阻害剤
|
WO2010048207A2
(en)
|
2008-10-21 |
2010-04-29 |
Metabolex, Inc. |
Aryl gpr120 receptor agonists and uses thereof
|
EP2393807B1
(en)
|
2009-02-04 |
2013-08-14 |
Boehringer Ingelheim International GmbH |
Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1
|
WO2010093191A2
(en)
|
2009-02-13 |
2010-08-19 |
Lg Life Sciences Ltd. |
Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
|
FR2943059A1
(fr)
|
2009-03-16 |
2010-09-17 |
Sanofi Aventis |
Derives de n-°6-aza-bicyclo°3.2.1!oct-5-yl)-aryl-methyl!- heterobenzamide,leur preparation et leur application en therapeutique
|
US8883832B2
(en)
|
2009-07-06 |
2014-11-11 |
Aerpio Therapeutics Inc. |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
EP2451808B1
(en)
|
2009-07-06 |
2014-03-26 |
Basf Se |
Pyridazine compounds for controlling invertebrate pests
|
BR112012001597A2
(pt)
|
2009-07-24 |
2015-09-01 |
Basf Se |
Método para controlar e/ou combater pestes de invertebrados, método para a proteção do material de propagação de planta e/ou das plantas que crescem do mesmo, material de propagação de planta e método para tratar ou proteger um animal de infestação ou infecção por parasitas
|
US9212177B2
(en)
|
2009-08-05 |
2015-12-15 |
Versitech Limited |
Antiviral compounds and methods of making and using thereof
|
EP2289883A1
(en)
|
2009-08-19 |
2011-03-02 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
KR20120081119A
(ko)
|
2009-09-04 |
2012-07-18 |
잘리커스 파마슈티컬즈 리미티드 |
통증 및 간질 치료를 위한 치환된 헤테로고리 유도체
|
US9095596B2
(en)
|
2009-10-15 |
2015-08-04 |
Southern Research Institute |
Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
|
EP2542081A4
(en)
|
2010-03-01 |
2013-07-31 |
Gtx Inc |
COMPOSITIONS FOR CANCER TREATMENT
|
US20130231348A1
(en)
|
2010-06-09 |
2013-09-05 |
Afraxis, Inc. |
8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS
|
WO2012058531A2
(en)
|
2010-10-29 |
2012-05-03 |
North Carolina State University |
Modulation of response regulators by imidazole derivatives
|
TWI408128B
(zh)
|
2010-12-03 |
2013-09-11 |
Nat Univ Tsing Hua |
間-三聯苯衍生物及其在有機發光二極體之應用
|
EP2655368A1
(en)
|
2010-12-20 |
2013-10-30 |
Irm Llc |
Compositions and methods for modulating farnesoid x receptors
|
JP2014500319A
(ja)
|
2010-12-20 |
2014-01-09 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
ファルネソイドx受容体を調節するための組成物および方法
|
CU24152B1
(es)
*
|
2010-12-20 |
2016-02-29 |
Irm Llc |
1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
WO2013037482A1
(en)
*
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
CN104781272A
(zh)
|
2012-06-19 |
2015-07-15 |
英特塞普特医药品公司 |
奥贝胆酸的制备、用途和固体形式
|
TWI621618B
(zh)
|
2013-03-13 |
2018-04-21 |
比利時商健生藥品公司 |
經取代2-氮雜雙環類及其作為食慾素受體調控劑之用途
|
WO2014181287A1
(en)
|
2013-05-09 |
2014-11-13 |
Piramal Enterprises Limited |
Heterocyclyl compounds and uses thereof
|
ME03082B
(me)
|
2013-05-14 |
2019-01-20 |
Intercept Pharmaceuticals Inc |
11-hidroksil-6-supsтituisani-derivati žučnih kiselina i njihovi aminoкiselinski konjugati као modulatori receptora za farnezoid х
|
CN105593237B
(zh)
|
2013-08-01 |
2019-06-04 |
美国卫生和人力服务部 |
法尼醇x受体的抑制剂和在医学中的用途
|
LT3043865T
(lt)
|
2013-09-11 |
2021-04-26 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Hepatito b viruso infekcijos gydymo būdai ir farmacinė kompozicija
|
US20150082981A1
(en)
|
2013-09-20 |
2015-03-26 |
E I Du Pont De Nemours And Company |
Capture of trifluoromethane using ionic liquids
|
CN104513213A
(zh)
|
2013-09-28 |
2015-04-15 |
山东亨利医药科技有限责任公司 |
Fxr激动剂
|
US20150119345A1
(en)
|
2013-10-29 |
2015-04-30 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of gastrointestinal infections
|
US9682939B2
(en)
|
2013-11-05 |
2017-06-20 |
Novartis Ag |
Compositions and methods for modulating farnesoid X receptors
|
WO2015116856A2
(en)
|
2014-01-29 |
2015-08-06 |
City Of Hope |
Farnesoid x receptor antagonists
|
WO2015138986A1
(en)
*
|
2014-03-13 |
2015-09-17 |
Salk Institute For Biological Studies |
Fxr agonists and methods for making and using
|
EP3116851B1
(en)
|
2014-03-13 |
2023-07-26 |
Salk Institute for Biological Studies |
Analogs of fexaramine and methods of making and using
|
US10077268B2
(en)
|
2014-03-13 |
2018-09-18 |
Salk Institute For Biological Studies |
FXR agonists and methods for making and using
|
US9879000B2
(en)
|
2014-04-14 |
2018-01-30 |
Grünenthal GmbH |
Heteroaryl substituted heterocyclyl sulfones
|
WO2015162538A1
(en)
|
2014-04-21 |
2015-10-29 |
Lupin Limited |
Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
|
WO2015162244A1
(en)
|
2014-04-25 |
2015-10-29 |
Basf Se |
N-acylamidine compounds
|
WO2015165960A1
(en)
|
2014-04-30 |
2015-11-05 |
Basf Se |
N-acylamidine compounds
|
MA39881B1
(fr)
|
2014-05-29 |
2020-02-28 |
Bar Pharmaceuticals S R L |
Dérivés de cholane à utiliser dans le traitement et/ou la prévention de maladies médiées par fxr et tgr5/gpbar1
|
CN104045635A
(zh)
|
2014-06-23 |
2014-09-17 |
华东理工大学 |
3,4,5-三取代异恶唑类化合物及其用途
|
US9855249B2
(en)
|
2014-10-02 |
2018-01-02 |
Flatley Discovery Lab, Llc |
Isoxazole compounds and methods for the treatment of cystic fibrosis
|
EP3006939A1
(en)
|
2014-10-06 |
2016-04-13 |
Gilead Sciences, Inc. |
Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
|
CN106716665B9
(zh)
|
2014-10-27 |
2018-12-07 |
株式会社Lg化学 |
有机电致发光器件
|
US10266560B2
(en)
|
2014-11-06 |
2019-04-23 |
Enanta Pharmaceuticals, Inc. |
Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
|
MY192927A
(en)
|
2014-11-21 |
2022-09-15 |
Akarna Therapeutics Ltd |
Fused bicyclic compounds for the treatment of disease
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
US11578097B2
(en)
|
2014-11-26 |
2023-02-14 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
|
WO2016086134A1
(en)
|
2014-11-26 |
2016-06-02 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
KR20170099909A
(ko)
|
2014-11-26 |
2017-09-01 |
이난타 파마슈티칼스, 인코포레이티드 |
Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
|
EP3034499A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Novel FXR (NR1H4) modulating compounds
|
EP3034501A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Hydroxy containing FXR (NR1H4) modulating compounds
|
KR20170095965A
(ko)
|
2014-12-18 |
2017-08-23 |
노파르티스 아게 |
간 및 위장 질환의 치료에 사용하기 위한 fxr 효능제로서의 아자비시클로옥탄 유도체
|
CA2972919A1
(en)
|
2015-01-09 |
2016-07-14 |
Gilead Apollo, Llc |
Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
|
ES2907461T3
(es)
|
2015-01-20 |
2022-04-25 |
Boehringer Ingelheim Animal Health Usa Inc |
Compuestos antihelmínticos, composiciones y procedimientos de uso de los mismos
|
TWI698430B
(zh)
|
2015-02-13 |
2020-07-11 |
南北兄弟藥業投資有限公司 |
三環化合物及其在藥物中的應用
|
US10100285B2
(en)
|
2015-04-03 |
2018-10-16 |
Propagenix Inc. |
Ex vivo proliferation of epithelial cells
|
CN106146483A
(zh)
|
2015-04-23 |
2016-11-23 |
上海迪诺医药科技有限公司 |
杂环类法尼酯衍生物x受体调节剂
|
GB201507340D0
(en)
|
2015-04-29 |
2015-06-10 |
Univ St Andrews |
Light emitting devices and compounds
|
US20180192651A1
(en)
|
2015-07-13 |
2018-07-12 |
Vanderbilt University |
Thermal volatilization of orco agonists
|
CA2998372A1
(en)
|
2015-09-11 |
2017-03-16 |
Chengkang ZHANG |
Ex vivo proliferation of epithelial cells
|
JP6817305B2
(ja)
|
2015-12-04 |
2021-01-20 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
アペリン受容体アゴニストおよびその使用方法
|
WO2017097870A1
(de)
|
2015-12-11 |
2017-06-15 |
Bayer Cropscience Aktiengesellschaft |
Substituierte malonsäureamide als insektizide
|
CN106946867B
(zh)
|
2016-01-06 |
2019-11-12 |
广州市恒诺康医药科技有限公司 |
Fxr受体调节剂及其制备方法和用途
|
EP3190103A1
(en)
|
2016-01-08 |
2017-07-12 |
Rijksuniversiteit Groningen |
Inhibitors of the pd-1/pd-l1 protein/protein interaction
|
EP3400229B1
(en)
|
2016-01-10 |
2024-03-06 |
Provincial Health Services Authority |
18/19f-labelled compounds which target the prostate specific membrane antigen
|
WO2017122209A2
(en)
|
2016-01-12 |
2017-07-20 |
Yeda Research And Development Co. Ltd. |
NF-kappaB INHIBITORS
|
WO2017128896A1
(zh)
|
2016-01-26 |
2017-08-03 |
江苏豪森药业集团有限公司 |
Fxr激动剂及其制备方法和应用
|
CN107021958A
(zh)
|
2016-02-01 |
2017-08-08 |
山东轩竹医药科技有限公司 |
Fxr受体激动剂
|
CN108602811B
(zh)
|
2016-02-01 |
2021-11-16 |
轩竹生物科技有限公司 |
Fxr受体激动剂
|
CN107021957A
(zh)
|
2016-02-01 |
2017-08-08 |
山东轩竹医药科技有限公司 |
Fxr受体激动剂
|
TW201741307A
(zh)
|
2016-02-22 |
2017-12-01 |
艾洛斯生物製藥公司 |
Fxr調節劑及其使用方法
|
CN107224583A
(zh)
|
2016-03-24 |
2017-10-03 |
中美华世通生物医药科技(武汉)有限公司 |
药物组合物及其用途
|
WO2017189663A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
WO2017189652A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
WO2017189651A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
WO2017201155A1
(en)
|
2016-05-18 |
2017-11-23 |
Enanta Pharmaceuticals, Inc. |
lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
|
US10138228B2
(en)
|
2016-05-18 |
2018-11-27 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use therof
|
US10144729B2
(en)
|
2016-05-18 |
2018-12-04 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as FXR agonists and methods of use thereof
|
SG10202012080UA
(en)
|
2016-06-03 |
2021-01-28 |
Chemocentryx Inc |
Method of treating liver fibrosis
|
CA2968836A1
(en)
|
2016-06-13 |
2017-12-13 |
Gilead Sciences, Inc. |
Fxr (nr1h4) modulating compounds
|
MX2018015443A
(es)
|
2016-06-13 |
2019-04-11 |
Gilead Sciences Inc |
Compuestos moduladores de fxr (nr1h4).
|
US10975056B2
(en)
|
2016-06-13 |
2021-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Substituted pyridines as inhibitors of DNMT1
|
AR108711A1
(es)
|
2016-06-13 |
2018-09-19 |
Gilead Sciences Inc |
Compuestos moduladores de fxr (nr1h4)
|
TW201808283A
(zh)
|
2016-08-05 |
2018-03-16 |
廣東東陽光藥業有限公司 |
含氮三環化合物及其在藥物中的應用
|
WO2018039384A1
(en)
|
2016-08-23 |
2018-03-01 |
Ardelyx, Inc. |
Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators
|
US10793568B2
(en)
|
2016-08-23 |
2020-10-06 |
Ardelyx, Inc. |
Hormone receptor modulators for treating metabolic conditions and disorders
|
CN108430998B
(zh)
|
2016-09-28 |
2021-07-09 |
四川科伦博泰生物医药股份有限公司 |
氮杂双环衍生物及其制备方法和用途
|
US20200045972A1
(en)
|
2016-09-29 |
2020-02-13 |
Bayer Cropscience Aktiengesellschaft |
Novel 5-substituted imidazolylmethyl derivatives
|
AU2017338853A1
(en)
|
2016-10-04 |
2019-04-18 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as FXR agonists and methods of use thereof
|
KR20230156159A
(ko)
|
2016-10-18 |
2023-11-13 |
마드리갈 파마슈티칼스, 인크. |
Thr-베타 아고니스트로 간 질환 또는 지질 질환을 치료하는 방법
|
CN107973790A
(zh)
|
2016-10-22 |
2018-05-01 |
合帕吉恩治疗公司 |
杂环fxr调节剂
|
WO2018087599A1
(en)
|
2016-11-10 |
2018-05-17 |
Galmed Research And Development Ltd. |
Treatment for fibrosis
|
AU2017356160A1
(en)
|
2016-11-11 |
2019-05-23 |
Gilead Sciences, Inc. |
Methods of treating liver disease
|
CN106588804B
(zh)
|
2016-12-09 |
2018-11-09 |
都创(上海)医药科技有限公司 |
一种作为类法尼醇x受体(fxr)的化合物的制备方法
|
CN106632294A
(zh)
|
2016-12-15 |
2017-05-10 |
宁波百纳西药业有限公司 |
一种螺环化合物及其药物用途
|
CN106748922B
(zh)
|
2017-01-12 |
2019-02-01 |
中国药科大学 |
一类新型砜酸衍生物、其制备方法及其作为药物的用途
|
US20180280394A1
(en)
|
2017-03-28 |
2018-10-04 |
Gilead Sciences, Inc. |
Methods of treating liver disease
|
WO2018190643A1
(en)
|
2017-04-12 |
2018-10-18 |
Il Dong Pharmaceutical Co., Ltd. |
An isoxazole derivatives as nuclear receptor agonists and used thereof
|
EP3609496A1
(en)
|
2017-04-12 |
2020-02-19 |
Gilead Sciences, Inc. |
Methods of treating liver disease
|
FI3911647T3
(fi)
|
2019-01-15 |
2024-03-01 |
Gilead Sciences Inc |
Isoksatsoliyhdiste fxr-agonistina ja sitä käsittäviä lääkekoostumuksia
|
CA3233305A1
(en)
|
2019-02-19 |
2020-08-27 |
Gilead Sciences, Inc. |
Solid forms of fxr agonists
|
AU2020234929B2
(en)
|
2019-03-11 |
2023-09-14 |
Gilead Sciences, Inc. |
Formulations of a compound and uses thereof
|